Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

10 May 2016 - 16 May 2016
11 May 2016 - 13 May 2016

European Partners Combine to Bring Therapeutic Antibody to Market

By BiotechDaily International staff writers
Posted on 15 Aug 2013
Print article
Two European biotechnology companies have agreed to collaborate to complete development and commence marketing of a novel therapeutic antibody that targets the GD2 antigen, which is abundantly expressed on neuroblastoma cells.

Neuroblastoma is a cancer of the sympathetic nervous system that accounts for about 7% of all childhood cancers and 10% to 15% of all childhood cancer deaths.

Apeiron Biologics AG (Vienna, Austria), a biotech company focused on immunologic and biologic therapies against cancer, has agreed to a joint project with Rentschler Biotechnologie GmbH (Laupheim, Germany), a full service biopharmaceutical contract manufacturer, to complete development of the chimeric APN311 antibody for advanced clinical studies and then to manufacture it under full GMP compliance.

Per the agreement, Apeiron will receive access to experienced teams, appropriate mammalian cell culture capacity for clinical phase I to III trials, commercial production, fill and finish services as well as a scientifically driven, and responsive project management. The manufacturing process, validation, and regulatory affairs will be transferred to Rentschler.

Hans Loibner, CEO of Apeiron Biologics, said, "We are happy to have identified Rentschler as a professional contract manufacturer and consider this collaboration as a distinct value increase for our project APN311, which is also acknowledged in discussions with existing and potential partners. This decision resolved a significant hurdle in our effort to make this therapy available as soon as possible. I am very much looking forward to a fruitful collaboration."

"We are very excited to contribute our expertise to meet the truly challenging timeline of this project which is so very important for children suffering from this life threatening disease," said Frank Ternes, chief business officer at Rentschler. "We are confident that this cooperative atmosphere will continue to grow and mature over the course of the entire project, and ensure the success of this partnership."

Related Links:
Apeiron Biologics AG
Rentschler Biotechnologie GmbH



Print article

Channels

Genomics/Proteomics

view channel
Image: A confocal microscopy image of human fibroblasts derived from embryonic stem cells. The nuclei appear in blue, while smaller and more numerous mitochondria appear in red (Photo courtesy of Dr. Shoukhrat Mitalipov, Oregon Health & Science University).

Stem Cells Derived from Older Individuals May Carry Unsafe Mitochondrial DNA Mutations

Induced pluripotent stem cells (iPSCs) derived from the skin fibroblasts of older individuals have a likelihood of harboring mitochondrial DNA mutations, which may render them unfit for clinical applications.... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel

Huge Modifiable Biomedical Database to Be Available on the Wikidata Site

Genome researchers are exploiting the power of the open Internet community Wikipedia database to create a comprehensive resource for geneticists, molecular biologists, and other interested life scientists. While efficiency in generating scientific data improves almost daily, applying meaningful relationships between... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.